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ABSTRACT 
The actions of glucagon have been extensively studied for many years. In 
heart, it is well established that glucagon is capable of causing inotropy. This action is 
mediated by glucagon binding to a G-protein coupled receptor (GPCR) which 
activates adenylate cyclase, increasing the intracellular concentrations of cAMP. The 
studies that were able to show this effect used concentrations of glucagon that were 
considered to be much higher than what is normally found in blood. A recent report, 
by Harney and Rodgers (2008), described the actions and signaling mechanisms of 
physiological concentrations of glucagon (<10-10 M) on perfused rat hearts. These 
investigators were also able to show that a peak physiological concentration of 
glucagon (10-10 M) increased glucose uptake in the same preparation. It was also 
found that this action was mediated by the activation of the PI3K/AKT signaling 
pathway. The missing piece of this mechanism to fully show glucagon’s action is the 
receptor responsible for glucagon binding and initiation of the reported downstream 
signaling effects. We hypothesize that one of two situations would occur: 1) the 
glucagon receptor that mediates glucose uptake is a GPCR or 2) there is a novel 
glucagon receptor responsible for the effects observed at low concentrations. Hearts 
were removed from male Sprague Dawley rats (n=1-6/grp) and isolated heart 
perfusion methods, either Langendorff or working mode, were used to deliver a 
physiological solution to the heart. Specific concentrations of hormone, one which 
represents peak physiological glucagon levels and another that represents a 
concentration of glucagon too high to be normally found in blood, were added to the 
physiological solution. An anti-glucagon receptor antibody was obtained which was 
  
used to block the known glucagon receptor. Hearts were treated with no hormone or 
with the following treatments: 1) 10-10 M glucagon; 2) 4x10-10 M insulin; 3) 10-8 M 
glucagon; 4) 10-8 M glucagon plus antibody and 5) 10-10 M glucagon plus antibody. 
Immediately after perfusion, hearts were processed and probed for AKT activation. It 
was found that glucagon concentrations at 10-10 M did not induce an inotropic 
response during Langendorff perfusion, while glucagon concentrations at 10-8 M was 
able to. For working mode, an inotropic response was not observed when hearts were 
perfused with 10-10 M glucagon and 10-8 M glucagon. There was no observable 
activation in AKT after physiological glucagon treated hearts in either Langendorff or 
working mode perfusion methods. In conclusion, the receptor that mediates 
glucagon’s actions at physiological concentrations was not able to be characterized 
from these experiments. Experimental strategy should be revised to optimize ex vivo 
heart perfusion method and include additional in vitro experiments to conclude the 
identity of the glucagon receptor.  
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CHAPTER 1 
 
INTRODUCTION 
Glucagon is a 29-amino acid peptide that is manufactured in alpha cells of the 
pancreas (Jiang and Zhang, 2003). This peptide is a vital player in regulating glycemia 
by acting in opposition to the effects of insulin. When blood glucose and insulin are 
low, the tonic inhibitory effect of insulin is removed and glucagon can be released 
from the pancreas (Taborsky, 2010). Glucagon is transported in the blood to its 
primary effector organ, the liver. As the ratio of glucagon to insulin increases, 
glucagon’s action will be more prominent than insulin’s action (Unger, 1971). The 
major effect of glucagon is to promote glucose output by increasing glycogenolysis 
and gluconeogenesis. In addition, glucagon can also act on the heart and adipose tissue 
by increasing contractility and lipolysis, respectively (Rodgers, 2012).  
 A G-protein coupled receptor (GPCR) is the main molecular target for 
glucagon (Jiang and Zhang, 2003; Rodgers, 2012). GPCR’s are a type of receptor that 
contains a seven-transmembrane domain plus a heterotrimeric G-protein complex 
(Salazar et al., 2007). When glucagon binds to a GPCR, a signaling cascade is 
initiated. First, Gαs subunits are activated and dissociate from the G-protein complex, 
which causes an increase in cyclic adenosine mono-phosphate (cAMP) by increasing 
the activity of a membrane-bound enzyme called adenylate cyclase (AC). cAMP then 
activates protein kinase A (PKA) by binding to the regulatory subunit causing it to 
dissociate from the catalytic subunit. PKA can phosphorylate certain proteins which 
causes an action at the specific organ (Rababa’h et al., 2014; Towle, 2001).  
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 The action of glucagon has been studied for many decades. The known actions 
of glucagon on liver, adipose tissue, and heart occur when glucagon binds to a GPCR 
to activate the AC/cAMP dependent pathway. The problem with these described 
actions is that they only occur at supra-physiological (glucagon concentration 
>0.1nM) levels, which do not reflect the physiologic concentrations (glucagon 
concentration <0.1nM)  found in vivo (Rodgers, 2012). This was illustrated by 
constructing average dose-response curves from numerous studies. For adipose and 
heart, the EC50 value of glucagon to produce the organ’s specific action, and the 
generation of cAMP, overlap each other and are well outside the concentration 
normally found in blood (Henry et al., 1975; Jean-Baptiste et al., 1982). This supports 
the claim that glucagon does not produce these actions in vivo.  For liver, the EC50 
value of glucagon to increase cAMP is well outside glucagon’s physiological 
concentration. However, it can be shown that glucagon can cause the liver to generate 
similar or identical responses at much lower concentrations without activating 
adenylate cyclase (Clark and Jarrett, 1978; Ikezawa et al., 1998a). Since the curves for 
glucose output and concentration of tissue cAMP do not overlap, one can make the 
assertion that glucagon’s action on the liver can occur through an alternative signaling 
mechanism in vivo. Collectively, these results raise the question about the 
“physiological relevance” of glucagon to produce these actions via the AC/cAMP 
dependent pathway. In order for a hormone’s action to be considered “physiologically 
relevant”, the action of the organ must occur at concentrations normally found in 
blood (Rodgers, 2012). It is evident from these graphs that glucagon can only generate 
cAMP-dependent cellular effects when concentrations are well above physiological 
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levels. Thus, additional research should be conducted to elucidate the physiological 
action of glucagon in liver, adipose tissue, and heart.  
 Studies have shown in liver that physiological and supra-physiological 
concentrations of glucagon activate two different signaling pathways but cause the 
same action (Livingston et al., 1985; Wakelam et al., 1986). The first piece of 
evidence comes from dose-response curves. Glucagon at physiological concentrations 
was able to increase glucose output without any increase in cAMP in perfused rat 
livers (Pilkis et al., 1974). Binding studies were also performed and it was found that 
supra-physiological glucagon concentrations were needed to activate the lower affinity 
glucagon receptor linked to AC. In the study performed by Bonnevie-Nielsen and 
Tager (1983), they determined Kd values for two different population of glucagon 
receptors. The Kd values of the low affinity glucagon receptor was 0.54 nM in 
hepatocytes and 92 nM in liver vesicles. Both these Kd values are above physiological 
concentrations. The high affinity receptor had Kd values of 0.19 nM and 2.6 nM in 
hepatocytes and liver vesicles respectively (Bonnevie-Nielsen and Tager, 1983). At 
physiological concentrations, glucagon binds with higher affinity to a receptor not 
linked to AC. It was found that the high affinity receptor participated in a calcium-
dependent signaling pathway that also increased glucose output (Ikezawa et al., 
1998b). A molecular cloning study was performed to identify the receptor that binds to 
glucagon. The experimenter expressed the glucagon receptor in kidney cell lines and 
measured Kd values. According the Schatchard plot they developed, they found two 
Kd values for the glucagon receptors that they expressed. However, the authors were 
not able to conclude that the receptors were anything other than the GPCR (Jelinek et 
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al., 1993). Thus, one prominent hypothesis is that two glucagon receptors are GPCRs, 
with two different affinities to glucagon, that can either undergo the AC/cAMP or 
PLC/IP3 signaling pathways.  
 Adipose tissue also has been shown to respond to glucagon at supra-
physiological concentrations via the cAMP/AC dependent pathway. However, the 
available evidence does not support the existence of a physiological receptor for 
glucagon in adipose tissue. The average dose response curves produces a monophasic 
curve with an EC50 that lies well outside physiological glucagon concentrations (Jean-
Baptiste et al., 1982). Furthermore, the average EC50 and Kd was calculated from 
many studies and it was shown that these values were similar (Rodgers, 2012). The 
similar values show that an additional receptor is not present in adipose tissue.  Thus, 
it is believed that glucagon does not have any action in vivo on adipose tissue.  
It has been demonstrated multiple times, and in many experimental models, 
that glucagon causes the heart to generate more force at a faster rate. Because of this, 
the claim has been made that glucagon’s acts to activate inotropic and chronotropic 
responses on the heart, both which are accompanied by increase in cAMP. Dr. Robert 
Rodgers and his colleagues believe that these effects cannot be the in vivo action of 
glucagon because concentrations above physiological levels are needed for this to 
occur. Dr. Rodgers constructed a concentration-effect curve that represents the 
findings of multiple sources to show the action of glucagon on the heart (Rodgers, 
2012). From his curve, he shows that EC50 values for inotropy and cAMP 
concentration both lie well outside of the glucagon concentration found in blood. 
Thus, his laboratory was interested in seeking out glucagon’s in vivo cardiac action. 
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They found that at physiological glucagon concentrations, glycolysis increased and 
palmitate oxidation decreased in isolated perfused working hearts (Harney and 
Rodgers, 2008).  These actions are the same as insulin’s actions and our experiments 
showed  that there was no statistical difference between the actions produced by either 
glucagon or insulin (Harney and Rodgers, 2008; Rodgers et al., 2001a). Furthermore, a 
physiological glucagon concentration activated a PI3K/AKT pathway but had no 
effect on the cAMP/AC pathway. This is another component that is shared between 
glucagon and insulin (Harney and Rodgers, 2008; Saltiel and Kahn, 2001). they were 
able to show that glucagon mimics the action of insulin, rather than opposing it, in 
heart at a physiological concentration.  
 The glucagon receptor that mediates the insulin-like response has yet to be 
identified. The purpose of this investigation was to begin to explore the identity of this 
receptor by performing heart perfusions followed by western blot analysis. The 
isolated heart perfusion method was used because the physiological parameters of the 
heart could be measured independent of any neuro-hormonal influence, the heart is in 
an environment where all substrates and substrate levels are known, and without an 
confounding effects from other metabolically active organs (Skrzypiec-Spring et al., 
2007). Hearts were treated with specific concentrations of hormone (physiological or 
supra-physiological) and contractility was measured to see if the hormone could 
activate the known GPCR. To block the known GPCR, an anti-glucagon GPCR 
antibody was obtained and put into a solution that was perfused through the heart. 
Hearts were then subjected to western blot analysis after perfusion experiments to 
show AKT activation. We hypothesized: 1) A GPCR linked to PI3K/AKT mediates 
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the insulin-like action of glucagon or 2) A receptor of a different class linked to 
PI3K/akt mediates the insulin-like action of glucagon. 
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CHAPTER 2 
 
METHODOLOGY 
Methods:  
Animal usage: 
 All procedures for the use of animals were approved by the University of 
Rhode Island Animal Care and Use Committee. Male rats were purchased from 
vendors (Taconic or Charles River). Animals were co-housed in standard cages with a 
12-hour light-dark cycle. They provided water and standard chow ad libitum., and 
body weights were collected routinely.  
 
Preparation of solutions: 
 
Hearts were perfused with Krebs-Henseleit (K-H) solution with the following 
composition (mM): NaCl, 120; CaCl2•2H2O, 1.8; NaH2PO4•H2O 1.2; MgSO4•7H2O, 
0.65 and KCl, 5.6, glucose, 10; and NaHCO3, 25. Working and Langendorff heart 
preparations were perfused with K-H solution containing 3% and 0.1% BSA, 
respectively.  In both preparations, the solution was gassed with 95-5% O2-CO2 
 Hearts were treated with one of the following: 1) no hormone; 2) insulin 
(4x10-10M) (Sigma-Aldrich); 3) and glucagon (10-10 or 10-8M) (Sigma-Aldrich). The 
lower and higher glucagon concentrations represented physiological and supra-
physiological concentrations (Rodgers, 2012).  
 
Isolated Heart Perfusion:  
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 The isolated heart perfusion technique was used to measure the hearts 
contractility when administering different treatments. The two types of perfusion 
techniques used were the Langendorff (Skrzypiec-Spring et al., 2007) and the working 
mode preparation (Harney and Rodgers, 2008; Rodgers et al., 2001b), both which 
have been described previously. Both preparation allows for the delivery of K-H 
solution to the coronary arteries of the heart so it can contract without being inside the 
animal. The pressure produced during perfusion was measured using a Millar catheter 
(SPR-524) inside a K-H solution filled column which was connected to the left 
ventricle. Pressure data was collected using Data Translation software (Colorado 
Springs, CO) and the data was analyzed using ADinstruments Lab Chart software. At 
the end of the perfusion, hearts were snapped frozen in liquid nitrogen and store in -
80oC freezer.  
 
Western Blot and AKT probing: 
 The procedure used to isolate proteins from the heart tissue was established 
by Harney and Rodgers (2008). Briefly, left ventricles of the heart were isolated then 
added to a lysis buffer containing the following solutes (mM) NaCl – 150; Tris-HCl – 
50; NaVO4 – 1; EDTA – 5; PMSF – 1; and protease tablet. Tissues were homogenized 
and centrifuged at the following speeds (times g): 1,000; 100,000; and 15,000. The 
final solution contained only soluble proteins. Proteins in solution were quantified 
using BCA assay kit.  
 Protein in solution were separated via SDS-PAGE. Equal amount of protein 
was added to each lane of a 10% gel and were electrophoresed at 100V. At the 
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completion of the electrophoresis, electroblotting was performed to transfer proteins 
from the polyacrylamide gel to a PVDF membrane. Electroblotting proceeded at 30V 
for 30 minutes.  
 Anti-AKT and anti-phospho-AKT (S473) were purchased from Cell 
Signaling Technologies and were used according to manufacturer’s protocol. Proteins 
were visualized using Biorad ChemiDoc imaging. ImageJ software was used to 
quantify the signal that was developed by the imaging software.      
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CHAPTER 3 
 
FINDINGS 
 
It is well established that high concentrations of glucagon are capable of 
inducing an inotropic response on the heart (Gonzalez-Muñoz et al., 2008; MacLeod 
et al., 1981; Rodgers et al., 1981). This response is mediated by the known glucagon 
GPCR linked to AC/cAMP. Physiological glucagon concentrations and insulin should 
not be able to induce this response (Fu et al., 2014; Harney and Rodgers, 2008). 
Therefore, we tested this theory by administering either 0.4 nM of insulin, 0.1 nM 
(physiological concentration) or 10nM (supra-physiological) of glucagon to isolated 
perfused hearts and measure the pressure produced by the left ventricle.  
Figure 1 is a representative pressure tracing of one heart perfused via the 
Langendorff preparation. From this figure, the left ventricular developed pressure 
(LVDP) can be determined by taking the difference between the peak systolic and 
diastolic pressures. The developed pressures were calculated for each heart and the 
average pressures were determined for each hormone group. The average LVDP 
values are represented in figure 2. Hearts that were perfused with no hormone had an 
average pulse pressure of 65.6 +/- 7.06 mmHg (mean +/- SEM). When 0.4nM insulin 
or 0.1nM of glucagon the pressure produced were 68.02 +/- 13.11 mmHg and 80.67 
+/- 19.78 mmHg, respectively. This is in line with what we were expecting because 
peak physiological concentration of either insulin or glucagon is not capable of 
inducing inotropy (Fu et al., 2014; Harney and Rodgers, 2008). Hearts produced the 
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largest inotropic response after administration of glucagon at supra-physiological 
concentrations, as expected. The pressure that was developed for supra-physiological 
glucagon administration was 133.11 +/- 6.67 mmHg. 
 Hearts that were perfused via working mode produced higher pressures, with 
all treatments, compare to hearts perfused in the Langendorff mode. Figure 3 is a 
representative pressure tracing of a heart perfused in the working mode. The same 
calculations were performed, as for figure 1, and average pressures were determined 
for each group and are represented in figure 4. Hearts produced pressures of 110.80 
+/- 10.7 mmHg, 100.85 mmHg, 90.95 +/- 24.6 mmHg and 92.96 +/- 4.18 mmHg when 
administered with no hormone, 0.4nM insulin, 0.1nM glucagon, and 10nM glucagon 
respectively. Unlike what was observed in hearts administered with 10nM glucagon 
via Langendorff perfusion, the average pressure of 10nM glucagon was less than that 
of control in the working mode. Figures 5 and 6 are representative tracings of a heart 
perfused with a supra-physiological glucagon concentration. It can be seen that an 
increase in contractility did occur. However, the response eventually decreased as the 
heart progressed through the perfusion which explains why the average pressure was 
less than control (figure 7).  
 It has been determined in this laboratory that, not only does a physiological 
concentration of glucagon mimic the same physiological action of insulin in the heart, 
but it also shares the same signaling pathway (Harney and Rodgers, 2008). It is well 
established that insulin binds to the insulin receptor which activates PI3K followed by 
AKT to increase glycolysis (Lee and Pilch, 1994). Evidence from this laboratory 
shows that glucagon at physiological concentrations also activates the PI3K/AKT 
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signaling pathway. Thus, we used this signaling pathway to assess the claim that 
changes in cardiac glycolysis could occur independently of changes in cardiac 
contractility with physiological concentrations of glucagon. The PI3K/AKT signaling 
pathway was quantified by measuring total amounts of AKT and the amount of 
phosphorylated AKT. A phosphorylated AKT:total AKT ratio was calculated to assess 
the activation of this signaling pathway when a hormone is given to the heart. For 
hearts perfused in Langendorff mode, an average P-AKT/T-AKT of 0.468 +/- 0.076 
(mean +/- SEM) was observed for untreated hearts. The highest P-AKT/T-AKT ratio 
that was observed was when insulin was administered to the hearts (0.561 +/- 0.128). 
Supra-physiological glucagon concentrations produced the second highest ratio of 
0.603 +/- 0.236. Administration of physiological glucagon produced the smallest a P-
AKT/T-AKT ratio of 0.221 +/- 0.032.  
 AKT quantification was also assed in hearts perfused in the working mode. A 
value of 0.468 +/- 0.076 was observed for untreated hearts. Administration of insulin 
to hearts gave the highest P-AKT/T-AKT ratio compared to the other groups (1.168). 
Supra-physiological glucagon produced the second highest P-AKT/T-AKT ratio of 
0.719 +/- 0.068. Finally, administering physiological glucagon produced an P-AKT/T-
AKT ratio of 0.472. +/- 0.099.   
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CHAPTER 4 
 
CONCLUSION 
 
The quintessential action of glucagon is to increase contractility of the heart. 
However, studies proved that this only happens at supra-physiological concentrations. 
In the laboratory of Dr. Robert Rodgers, they were able to find a different action of 
glucagon at physiological concentrations. Glucagon increased glucose uptake, glucose 
oxidation, and decreased palmitate oxidation to a degree similar to insulin (Harney and 
Rodgers, 2008; Rodgers et al., 2001a). Furthermore, physiological concentrations of 
glucagon activated the PI3K/AKT pathway without any activation of AC/cAMP 
(Harney and Rodgers, 2008). Therefore, we believe that increasing cardiac 
contractility is not the main in vivo action of glucagon.    
 The first objective of this study was to determine whether a supra-
physiological concentration of glucagon increases inotropy compared to physiological 
concentrations in Langendorff perfused hearts. A supra-physiological concentration of 
glucagon was able to produce an average LV pulse pressure that was greater compared 
to controls in Langendorff perfused hearts. Hearts perfused with a physiological 
concentration of glucagon or insulin produced LV pressures that were modestly 
elevated compared to control hearts. This result was consistent with previous reports 
(Harney and Rodgers, 2008; Tuncok et al., 1997).  Hearts perfused with any of the 
hormone treated groups, in working mode, did not produce an average LV pulse 
pressure that was larger compared to controls. An inotropic response was expected to 
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occur in hearts treated with supra-physiological glucagon concentrations because it 
has been previously reported that high glucagon concentrations increase developed 
tension or pressure in rat hearts or cardiac muscle preparations  (MacLeod et al., 1981; 
Rodgers et al., 1981). Although the average response was not different, it appears that 
a transient inotropic response was produced. This observation can be explained by 
glucagon’s tachyphylaxis response. Tachyphylaxis response, in heart, occurs when 
there is a rapid increase in left ventricular pressure which is then decreases back to 
baseline shortly after (MacLeod et al., 1981). This response occurs in G-protein 
signaling due to either receptor desensitization or by activity of phosphodiesterases 
that degrades cAMP. Fita-Juan and colleagues (2004), studied the tachyphylaxis 
response in isolated right ventricle strips in rats. When glucagon was added to these 
hearts, a transient (< 2min) inotropic response was induced (Juan-Fita et al., 2004). In 
this study, it was observed that the inotropic response was at its highest point one 
minute after glucagon administration, then rapidly decreased.  
 The second objective was to determine whether a physiological concentration 
of glucagon was able to activate the PI3K/AKT signaling pathway. We evaluated 
activation of PI3K/AKT pathway by quantifying phosphorylated AKT and total AKT 
via western blots.  For Langendorff and working mode perfused hearts, there appears 
to be no increase in AKT activation between physiological glucagon treated hearts 
compared to untreated hearts. This was contrary to Harney and Rodgers’s report which 
showed PI3K/AKT activation when hearts were perfused with low concentrations of 
glucagon. A physiological concentration of insulin produced more activation in AKT 
compared to untreated hearts in either Langendorff or working mode perfusion 
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methods. Due to the small number of subjects in the insulin treated group, the values 
obtained cannot definitively show that insulin was capable of activating AKT at a 
higher magnitude compared to untreated hearts.  
 Differences in methodology could explain the unexpected results that were 
observed in this experiment. One factor that may explain the discordant results is the 
difference in the age range of rats enrolled in each study. In the current experiment, 
the age was not recorded but, the age can be approximated using body weight (2017).  
Harney and Rodgers (2010), used rats that weighed between 200-400 grams which 
approximates to two to three months. In this experiment, it was noted that many of the 
animals that were used weighed over 400 grams with is approximately three months or 
older.  
 Another point that arises, due to the unexpected results, is whether or not the 
glucagon used was sufficient to activate AKT. The glucagon that was used may have 
lost intrinsic activity to activate the glucagon receptor, or, the dilution procedure was 
not accurate and low than expected concentrations of glucagon was administered to 
the perfused heart. A crucial experiment that can give evidence to the integrity of the 
glucagon solution was to perfuse hearts with 5-3H-glucose and measure the change in 
rate of glycolysis. If glucagon administration was able to activate glycolysis, but not 
PI3K/AKT, then it can be argued that glucagon’s physiological actions are not 
mediated by PI3K/AKT.    
 Aging can affect the biochemical and physiological parameters of this 
experiment. First, the strength of the PI3K/AKT signaling pathway could have 
decreased due to using older rats. Griecsova and colleagues (2015), showed that three-
 16 
 
month-old rats had a lower AKT activation than 1.5 months old rats (Griecsová et al., 
2015). In this study, several rats weighed over 400 grams which approximate to a 3-
month-old rat. This may explain why AKT activation was not as robust as expected 
after insulin treatment. This could also be a factor that cause physiological glucagon 
treated hearts to have a lower than expected AKT activation.  
A decline in cardiac performance can also be attributed to changes in the 
GPCR receptor signaling. These changes include reductions in the: 1) number of 
receptors, 2) sensitivity of the receptor and 3) downstream actions after receptor 
activation. In a study performed by Xiao et al (1998), they found that age related 
declines in LV contractility were due to decreases in the number of β-adrenergic 
receptors. It was also determined from this study that older rats have less AC activity 
compared to young rats when a ligand binds to the receptors (Xiao et al., 1998).  
Furthermore, heart contractility decreased due to changes in calcium handling after β-
adrenergic stimulation. It was found that calcium levels were decreased in older 
animals compared to younger ones which will reduce the strength of contraction 
(Ferrell and Howlittt 2007). It was shown that decreases in calcium levels during 
diastole can decrease the contraction force at the next heartbeat. Since the glucagon 
receptor is also a GPCR associated with AC, it can be expected that similar changes 
can occur due to aging which may have affected the hearts ability to contract.  
Fibrosis of heart tissue is another possible factor that may explain the lower 
than expected pressure produced by the hearts. Age-related fibrosis increases collagen 
deposits into the heart’s extracellular matrix and causes a decrease in performance. In 
ideal conditions, the extra cellular matrix plays an important role in maintaining the 
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organs structure that allows it to work normally (Heeneman et al., 2003). For certain 
conditions (i.e. aging) there may be an overproduction of extracellular matrix proteins 
which decreases the hearts ability to perform. In an experiment conducted by 
Sangaralingham et al., they showed that collagen production in the left ventricle was 
higher in 20-month-old Fisher rats than in two- months old rats (Sangaralingham et al., 
2016). This increase in fibrosis was accompanied by decreases in ejection fracture and 
decreases in diastolic wall tension.  
Evidence is also present that shows young Sprague-Dawely rats are prone to 
develop spontaneous cardiac lesions. In a study conducted by Chanut et al. (2013), 
they looked at the presence of lesions in different regions of the heart and they found 
the highest occurrence of lesions to be within the myocardium of the left ventricle. It 
was also reported that the stress from handling the rats had no effect on changing the 
occurrence of the lesions (Chanut et al., 2013). This can have an effect on the pressure 
generated by the heart. The presence of cardiac lesion can cause an inflammation 
response that may release factors which can decrease LV function. For example, it has 
been shown that TNF (a pro-inflammatory agent) infusion resulted in reduced 
inotropic response which was reversed when TNF was removed (Mann, 2002). 
Depending on the size and number of lesions in the heart, this may have contributed to 
the lower than expected pressure development of the left ventricle.   
 If this experiment was to be redone, a different approach for identifying the 
PI3K/AKT signaling pathway would be necessary. One method that can be utilized are 
cell culture techniques followed by western blot analysis to probe the same proteins. 
Isolated cardiomyocytes can be obtained from whole heart by perfusing it with 
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digestive enzymes via Langendorff perfusion (Louch et al., 2011). The isolated cell 
can then be plated onto a culture dish and be given culture media. In the culture media, 
different concentrations of hormone can be given to the cardiomyocytes and protein 
quantification can be determined via western blotting.  
Western blot analysis have been performed on hepatocytes and probed for 
AKT (Aw et al., 2014; Zhao et al., 2000). In these experiments, glucagon was not able 
to activate the PI3K/AKT signaling pathway. This observation can be explained by the 
fact that the receptors present in the liver are not linked to PI3K/AKT. However, this 
author was not able to find any reports that performed cell culture experiments on 
isolated ventricular cardiomyocytes treated with glucagon. Performing this method 
may provide evidence on the physiological signaling cascade of glucagon.  
 Instead of using ex vivo hemodynamics to measure the contractility of the 
heart, in vitro video edge detection of isolated ventricular cardiomyocytes could be 
used to measure a single myocyte’s ability to shorten (Bazan et al., 2010). There is 
evidence that the cardiomyocyte has glucagon receptors on it so the changes in 
contractility can be measure when cell are perfused with glucagon containing solution 
(Ali et al., 2015; Méry et al., 1990; Tang and Insel, 2004). It has the advantage over ex 
vivo measurements of contractility because the experimenter is directly measuring the 
ability of a single myocyte to shorten when given a certain stimulus. The contractility 
of many myocytes can be measured which may provide evidence for how the cells 
will function in the intact organ. A limitation of this method is that the results may not 
represent what is occurring at the organ level. Whole heart perfusion methods 
incorporate preload and after load, both which influence the tension that can be 
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developed in the LV (Schechter et al., 2014). Furthermore, measuring contractility in 
isolated cardiomyocytes does not represent how the heart may act in vivo because the 
cells are not connected to each other. Gap junctions are channels which connect the 
intracellular content between two cardiomyocytes. These channels allow ionic current 
to pass directly from one cardiomyocyte to another which allow the whole heart to 
contract in a synchronized manner (Rook et al., 1992). Interruption of this current 
through each cardiomyocyte can prevent the ventricles from depolarizing and thus fail 
to contract. Contractility can be measured using cell based experiments. Three-
dimensional cell culture techniques allow for an experimenter to grow cells that does 
not limit the cells to grow on a flat surface. Cells are able to form connections with 
each other that may closer replicate what happens in vivo. In a report by Shimizu et al., 
they were able to measure cell shortening in cultured cardiac tissue grafts by using a 
digital video camera (Shimizu et al., 2002).  
 
 Limitations: 
The surgical procedure used in this study was similar to the procedure 
performed by Harney and Rodgers (2010). The experimenter tried to replicate the 
same conditions that Harney used when performing the heart isolation, but the 
experimenter was not there to observe Harney perform the procedure. It was thought 
that differences in experimenter’s ability to isolate the heart could have contributed to 
the different results. Differences such as speed of heart isolation and location of 
cannula placed on the aorta could have affected the outcome of the procedure. Using 
anesthesia could have facilitated in the heart isolation process by reducing the stress 
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put on the animal. Minimizing the stress on the heart may reduce the damage put on 
the heart while the experimenter performs the heart isolation procedure. 
Another limitation of this experiment is that absolute pressure values were 
recorded, rather than changes in pressure relative to baseline. Changes in LV pulse 
pressure from baseline is a better marker for contractility. The reason is that there are 
many factors that can influence the amount of force the heart can produce; such as 
changes in pre-load and afterload, health of the heart, or quality of solutions used to 
treat heart. Contractility is the heart’s ability to increase the amount of force 
independent of pre-load and/or after load. Recording the change in LV pulse press will 
rule out some of the effects of extrinsic factors that may change the pressure the heart 
produces. With absolute pressures, we can see that different pressures are generated 
but we cannot fully conclude that the pressures generate was due to the heart’s 
intrinsic ability to develop more force.  
 
Conclusion 
  In summary, it cannot be determined if a high concentration of glucagon was 
able to induce an inotropic response. LV pressure was the highest in supra-
physiological treated hearts perfused in Langendorff mode. However, LV pressure 
was similar between untreated and supra-physiological glucagon administered hearts. 
The data also shows that there were no changes in AKT activation among the four 
groups. A limitation in this study that can explain why difference in measurements 
were not detected were due to the number of rats in each group. Since some of the 
treatment groups had less than four animals, statistics were not able to be performed to 
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determine if there was a difference in values for LV pressure development and AKT 
activation.  
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Figures  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 1: Representative pressure measurement for a heart perfused in the Langendorff 
preparation. This graph was shows the pressure produced by the left ventricle after 1 
minute of perfusion. The difference between the maximum and minimum pressure 
were averaged to determine pulse pressure. This heart was treated with no hormone.    
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Figure 2: Average pulse pressure produced by each treatment. Pulse pressure was 
determine by taking the difference of the average maximal pressure minus the average 
minimal pressure. Bars represent average values and error bars represent the SEM.  
 24 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Representative pressure measurement for a heart perfused in the working 
mode. This graph was shows the pressure produced by the left ventricle after 10 
minute of perfusion. The difference between the maximum and minimum pressure 
were averaged to determine pulse pressure. This heart was treated with no hormone.  
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  Figure 4: Average pulse pressure produced by each treatment. Pulse pressure was 
determined by taking the difference of the average maximal pressure minus the 
average minimal pressure. Bars represent average values and error bars represent SEM  
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Figure 5 
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Figure 6 
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Figure 7 
 
Figures 5, 6, and 7 are representative pressure tracings of one heart perfused via 
working mode. A supra-physiological glucagon concentration was administered at 
time zero. Each figure represents a different time point on the same heart. The 
pressure was determined by taking the difference of maximum value and the minimum 
value.  
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Figure 8: Average ratio of P-akt/T-akt for hearts perfused in the Langendorff Mode. 
Ratios represent the activation in PI3K/akt pathway. Error bars represent the SEM.  
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Figure 9: Average ratio of P-akt/T-akt for hearts perfused in the working Mode. Ratios 
represent the activation in PI3K/akt pathway. Error bars represent the standard 
deviation. Values represent means and error bars represent SEM 
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